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COST-EFFECTIVENESS OF BLOOD PRESSURE
AND URINARY ALBUMIN CONTROL IN
DIABETICS WITH AN ANGIOTENSIN II
RECEPTOR ANTAGONIST AND A CALCIUM
CHANNEL BLOCKER: PHARMACOECONOMIC
ANALYSIS OF THE MARVAL TRIAL—THE CASE
OF GERMANY
Smith DG1, Gnanasakthy A2, Quednau K3
1University of Michigan, Ann Arbor, MI, USA; 2Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA;
3Novartis Pharma GmbH, Nuremberg, Germany
OBJECTIVES: The objective of the study was to evalu-
ate the short-term costs and cost-effectiveness of initiat-
ing therapy with an angiotensin II receptor antagonist
compared to a calcium channel blocker in type II diabetic
patients with microalbuminuria. METHODS: An eco-
nomic model was developed based upon a multicenter,
randomized, double-blind, 24-week trial comparing the
angiotensin II receptor antagonist valsartan (n = 169)
with the calcium channel blocker amlodipine (n = 163) in
Type 2 diabetic patients with microalbuminuria. The
primary outcome measure was urinary albumin excretion
rate (UAER) and the secondary outcome measure was the
return to normoalbuminuric status. Resource use was col-
lected through study administration reports, adverse
event reports and concurrent medication reports. Costs
were applied to resources at German speciﬁc payment
rates for services and medications (EBM, GOÄ 2002 etc.).
RESULTS: Changes in UAER were 44.2% with valsartan
and 8.2% with amlodipine (p < 0.01). Changes in albu-
minuric status were 29.9% with valsartan and 15.5%
with amlodipine (p < 0.01). Blood pressure was equally
controlled with both medications. HbA1c remained
stable and did not differ between treatments. With costs
expressed in EUR (€), total costs were €638.18 with val-
sartan and €503.66 with amlodipine. Incremental cost-
effectiveness ratios were 374 for changes in UAER and
874 for changes in albuminuric status. CONCLUSIONS:
Use of valsartan compared to amlodipine in diabetics
with microalbuminuria was associated with signiﬁcantly
improved UAER and albuminuric status at similar total
treatment costs. The combination of signiﬁcantly higher
efﬁcacy and higher costs yields incremental cost-
effectiveness ratios that are favorable for the use of val-
sartan over amlodipine.
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PREDICTED COSTS AND OUTCOMES FROM
REDUCED VIBRATION DETECTION IN PEOPLE
WITH DIABETES IN THE UK
Shearer A1, Scuffham P1, Gordois A1, Oglesby A2
1University of York,York, United Kingdom; 2Eli Lilly &
Company, Indianapolis, IN, USA
OBJECTIVE: The ability to perceive vibration (vibration
detection) has been shown to be a good predictor of long-
term complications among patients with diabetic periph-
eral neuropathy (DPN). The aim of the study was to esti-
mate the predicted complications and costs for the NHS
associated with reduced vibration detection. METHODS:
A Markov model of DPN progression was constructed
for a hypothetical cohort of people with DPN. The model
was run over a 10-year period using Monte Carlo simu-
lations to estimate disease progression, predicted costs,
life-years and quality-adjusted life-years (QALYs) accord-
ing to vibration detection levels. Rates of foot ulceration
and amputation, the probability of healing, and health
state utility scores were identiﬁed by undertaking a
focused literature search. The cost data used in the model
were derived from a concurrent cost of illness study.
RESULTS: Discounted over ten-years, the average indi-
vidual with reduced vibration detection incurs approxi-
mately 3.3 times more direct medical costs for foot ulcers
and amputations (£1531 vs. £457), yields 0.19 fewer
QALYs, and lives for approximately 2 months shorter
than an average individual with normal vibration detec-
tion. The long-term complications of DPN (foot ulcers
and amputations) experienced by the population with
reduced vibration detection will cost the NHS approxi-
mately £292m (discounted) over the next 10 years. CON-
CLUSIONS: Effective treatment of foot ulceration and
amputation is time-consuming and expensive. If at-risk
individuals with reduced vibration detection could be
identiﬁed and targeted for intervention, valuable Health
care resources could be saved and improved health out-
comes should result. For example, if all individuals in the
UK with diabetes and reduced vibration detection were
identiﬁed and their risk of ulceration and amputation
reduced to levels experienced by those with normal vibra-
tion detection, this could save the NHS up to £204m, and
save 29,000 life-years and 36,000 QALYs (discounted)
over the next ten years.
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Niewada MP1, Glogowski CA2, £atek M3, Pietrasik A3,
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OBJECTIVES: The Cost Of Diabetes type 2 in Poland
(CODIP) study is the ﬁrst attempt aimed at valuating clin-
ical characteristics and total costs associated with type 2
diabetes in Poland. Study design reﬂects that of CODE 2
(Cost Of Diabetes in Europe type2) and allows for inter-
national comparison. METHODS: Three hundred-three
patients randomly enrolled, (mean age: 61, mean time
from diagnosis: 10.86 year, males: 49%) were divided
into 4 categories: no complications, one or more micro-
vascular complications, one or more macrovascular 
complications, one or more of each microvascular and
macrovascular complications. Direct cost associated with
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complications was assessed for the last six months.
RESULTS: CODIP patients totaling 79.3% had at least
one complication, 21.7% having microvascular only,
17.5% macrovascular only, 40% having both microvas-
cular and macrovascular complications. The prevalence
of microvascular complications: foot ulcer 6.9% (ampu-
tations performed in 2.6%), 1-eye retinopathy 7.3%,
both-eyes 17.2%, photocoagulation 9.9%, vitrectomy
1.7%, microalbuminuria 19.1%, manifested nephropa-
thy 11.9%, dialysis 0.3%, neuropathy 41.9%. The preva-
lence of macrovascular complications: coronary artery
disease 42.6% (unstable angina 4.9%), myocardial
infarction 14.2%, heart failure 15.5%, PTCA 2.3%,
CABG 3.0%, TIA 5.0%, PAD 30.7%. Mean cost, in 6
months observations, for patients with no complica-
tions amounted to €498 (PPP value: €1 = 1.9 PLN). Cost
impact factor for microvascular only, macrovascular only
and microvascular and macrovascular, as compared to
patients with no complications were estimated at 1.54,
1.52, and 2.02, respectively. CONCLUSIONS: Compli-
cations have a substantial impact on direct cost of dia-
betes type 2.
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ADVANCED TOOLS FOR ALLOCATION OF
MEDICAL PRODUCTS: ECONOMIC
EVALUATION OF THE “HOMECARE”
PROGRAMME
de Portu S1, Gradnik PA2, Recchia A2, Munna E2,
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OBJECTIVES: In 2000 an electronic prescription service
called “Homecare” was established in the Local Health
Unit (LHU; 920.196 inhabitants) of Legnano (Italy) in
order to manage the distribution of devices for diabetes
care directly through private pharmacies. The objective
was to evaluate if the allocation of the medical products
through “Homecare-Legnano” resulted in savings to the
LHU. METHODS: We created an “Index of Saving” (IS),
calculated as the ratio between the difference from actual
and budgeted and budgeted: IS = [(actual - budgeted)/
budgeted], in which “budgeted” is the number of devices
that each patient can theoretically receive every month
and “actual” is the number of devices that each patient
actually received. The IS value ranged from +1 to 0 and
can be interpreted as the percentage saving obtained in
the allocation of medical products for the LHU system.
We performed an economic evaluation of the savings, in
monetary terms for medical products, paid out through
“Homecare” for the period January to December 2001.
To verify if the savings, both in physical (IS) terms and in
monetary terms were signiﬁcantly different from 0, we
conducted a statistical analysis using a “Student t” test.
RESULTS: More than 17,000 patients used the Home-
care service through the 197 private pharmacies, which
were involved in the project. Twenty different types 
of medical products were distributed for a total of
2,668,582 devices. The mean value of IS for medical
products per month was -0.134, i.e. a saving in the allo-
cation of medical products of 13.4%. This value was sig-
niﬁcantly different from 0 (CI 95% -0.1585; -0.1101 
P < 0.0001) corresponding to a monetary saving of
€29.74 per patient-year. CONCLUSIONS: The “Home-
care Legnano” programme simpliﬁed the procedures for
allocation of diabetic medical products and simultane-
ously resulted in savings in monetary terms for the LHU.
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A COST-UTILITY ANALYSIS OF INSULIN
GLARGINE (LANTUS®) IN THE TREATMENT OF
PATIENTS WITH TYPE 1 DIABETES
Kristensen FK1, Sverre JM1, Bustad S2
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OBJECTIVES: To estimate the cost per quality adjusted
life year (QALY) with insulin glargine (LANTUS) com-
pared with NPH insulin in the treatment of patients with
Type 1 diabetes in Norway. An impediment to adequate
management of patients with Type 1 diabetes has been
maintaining an appropriate balance between adequate
glycaemic control and the risk of hypoglycaemia, which
may have a serious impact on quality of life. The ratio-
nale behind insulin glargine therapy is to facilitate this
trade-off by improving the probability of reaching gly-
caemic control targets, reducing frequency of hypo-
glycaemia (FoH), or both. METHODS: The model
(developed by Aventis Pharma) estimates the cost-utility
of insulin glargine versus NPH insulin over 9 years in
Norway. The yearly frequency of microvascular compli-
cations for NPH insulin treatment is based on data from
the DCCT. For insulin glargine, the effects on HbA1c
observed in clinical trials are used to estimate complica-
tion rates based on the relationship observed in the
DCCT. Estimates of QALYs lost are based on complica-
tion rates and frequencies of serious hypoglycaemic
events, and the impact on QALYs due to fear of hypo-
glycaemia (proportional to the frequency of events) is also
modelled. The cost perspective is societal, and Norwegian
costs of treatments and complications are utilized.
RESULTS: Under base-case assumptions (DHbA1c =
0.4%, DFoH = 15 events/patient—year, discount-rate
3%) the marginal cost/QALY is NOK 3700. Sensitivity
analyses based on the central parameters indicate the
analysis is stable. Even under conservative assumptions
(DHbA1c = 0.2% and a 60% reduction in the impact 
of fear of hypoglycaemia) the incremental cost/QALY
remains acceptable at < NOK 23,000. CONCLUSIONS:
Based on the assumptions in this model, the results indi-
cate that insulin glargine is a cost-effective alternative to
NPH insulin in patients with Type 1 diabetes.
